Mega Genomics

Mega Genomics ROA

The Return on Assets (ROA) of Mega Genomics (6667.HK) as of Oct 20, 2026 is 3.16 %. In the previous year, Return on Assets (ROA) was 6.10 % — a change of -48.16% (lower).

ROA

3.16 %

YoY

-48.16%

Last updated:

In 2025, Mega Genomics's return on assets (ROA) was 3.16 %, a -48.16% increase from the 6.10 % ROA in the previous year.

The Mega Genomics ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
11.26 CNY
Jan 1, 2020
17.44 CNY
Jan 1, 2021
8.77 CNY
Jan 1, 2022
-2.14 CNY
Jan 1, 2023
3.77 CNY
Jan 1, 2024
6.10 CNY
Jan 1, 2025
3.16 CNY
The Mega Genomics ROA history
YEARROAYoY
3.16 %-48.16%
6.10 %+61.75%
3.77 %-276.20%
-2.14 %-124.40%
8.77 %-49.70%
17.44 %+54.91%
11.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd. generates revenue through three business segments. The Consumer Genetic Testing Services segment offers nutrition and metabolism testing, cancer risk assessment, chronic disease susceptibility analysis, pharmacogenetic testing, and infectious disease testing to individual consumers. The Cancer Screening Services segment provides specific tests including Septin9 for colorectal cancer, Syndecan-2 (SDC2) for colorectal cancer, and ring finger protein 180 (RNF180)/Septin9 for gastric cancer screening. The Other Services segment delivers genetic research and analysis services to third-party research institutions, creating additional revenue streams from institutional partnerships. The primary buyers for Consumer Genetic Testing Services are individual consumers seeking personalized health insights. Cancer Screening Services are utilized by healthcare providers and patients for early detection of colorectal and gastric cancers. Third-party research institutions purchase genetic research and analysis services from the Other Services segment to support their scientific studies and development projects. Mega Genomics Ltd. serves distinct market segments: individual consumers for genetic testing, healthcare providers for cancer screening, and research institutions for specialized genetic analysis. The company's revenue model relies on direct consumer sales, healthcare provider contracts, and institutional research partnerships to sustain its operations and growth. Mega Genomics is one of the most popular companies on Eulerpool.

ROA Details

Understanding Mega Genomics's Return on Assets (ROA)

Mega Genomics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Mega Genomics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Mega Genomics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Mega Genomics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Mega Genomics stock

Return on Assets (ROA) of Mega Genomics is 3.16 % in 2025.

Return on Assets (ROA) of Mega Genomics changed from 6.10 % to 3.16 %, representing a -48.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Mega Genomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Mega Genomics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Mega Genomics